The Forefront of Maintenance Therapy for Newly Diagnosed Advanced Ovarian Cancer in China: A Review of Updated Evidence With PARP Inhibitors

IF 4.7 1区医学 Q1 OBSTETRICS & GYNECOLOGY

Bjog-An International Journal of Obstetrics and Gynaecology Pub Date : 2025-04-21 DOI:10.1111/1471-0528.18180

Lingling Xie, Shaodan Lin, Yunyun Liu, Xiaoting Ling, Zhongqiu Lin

{"title":"The Forefront of Maintenance Therapy for Newly Diagnosed Advanced Ovarian Cancer in China: A Review of Updated Evidence With PARP Inhibitors","authors":"Lingling Xie, Shaodan Lin, Yunyun Liu, Xiaoting Ling, Zhongqiu Lin","doi":"10.1111/1471-0528.18180","DOIUrl":null,"url":null,"abstract":"<div>\n \n \n <section>\n \n <h3> Background</h3>\n \n <p>In the first-line (1L) maintenance treatment of newly diagnosed advanced ovarian cancer (OC), poly (ADP-ribose) polymerase inhibitors (PARPi) have demonstrated significant benefits in progression-free survival (PFS) and an encouraging trend in overall survival (OS).</p>\n </section>\n \n <section>\n \n <h3> Objectives</h3>\n \n <p>To provide a summary of advances and evidence regarding the use of PARPi in the maintenance treatment of newly diagnosed advanced OC in the Chinese population.</p>\n </section>\n \n <section>\n \n <h3> Search Strategy</h3>\n \n <p>Systematic search of PubMed from January 2016 to June 2024.</p>\n </section>\n \n <section>\n \n <h3> Selection Criteria</h3>\n \n <p>Phase III randomized trials and real-world studies conducted in China were included.</p>\n </section>\n \n <section>\n \n <h3> Main Results</h3>\n \n <p>PARPi 1L maintenance studies conducted in China have shown that PARPi can prolong PFS in OC patients with manageable safety. Chinese patients differ from foreign patients in baseline characteristics and safety data. Given the current situation of 1L maintenance therapy in China, recommendations are made for maintenance strategies based on different biomarker status.</p>\n </section>\n \n <section>\n \n <h3> Conclusions</h3>\n \n <p>PARPi 1L maintenance therapy offers survival benefit to Chinese patients with newly diagnosed advanced OC. OC has become a chronic disease that requires the selection of appropriate maintenance regimens based on multiple factors.</p>\n </section>\n </div>","PeriodicalId":50729,"journal":{"name":"Bjog-An International Journal of Obstetrics and Gynaecology","volume":"132 S4","pages":"5-12"},"PeriodicalIF":4.7000,"publicationDate":"2025-04-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Bjog-An International Journal of Obstetrics and Gynaecology","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1111/1471-0528.18180","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"OBSTETRICS & GYNECOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Background

In the first-line (1L) maintenance treatment of newly diagnosed advanced ovarian cancer (OC), poly (ADP-ribose) polymerase inhibitors (PARPi) have demonstrated significant benefits in progression-free survival (PFS) and an encouraging trend in overall survival (OS).

Objectives

To provide a summary of advances and evidence regarding the use of PARPi in the maintenance treatment of newly diagnosed advanced OC in the Chinese population.

Search Strategy

Systematic search of PubMed from January 2016 to June 2024.

Selection Criteria

Phase III randomized trials and real-world studies conducted in China were included.

Main Results

PARPi 1L maintenance studies conducted in China have shown that PARPi can prolong PFS in OC patients with manageable safety. Chinese patients differ from foreign patients in baseline characteristics and safety data. Given the current situation of 1L maintenance therapy in China, recommendations are made for maintenance strategies based on different biomarker status.

Conclusions

PARPi 1L maintenance therapy offers survival benefit to Chinese patients with newly diagnosed advanced OC. OC has become a chronic disease that requires the selection of appropriate maintenance regimens based on multiple factors.

查看原文本刊更多论文

中国新诊断的晚期卵巢癌维持治疗的前沿：PARP抑制剂的最新证据综述

在新诊断的晚期卵巢癌（OC）的一线（1L）维持治疗中，聚（adp -核糖）聚合酶抑制剂（PARPi）在无进展生存期（PFS）和总生存期（OS）方面显示出显著的益处。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Bjog-An International Journal of Obstetrics and Gynaecology 医学-妇产科学

CiteScore

10.90

自引率

5.20%

发文量

345

审稿时长

3-6 weeks

期刊介绍： BJOG is an editorially independent publication owned by the Royal College of Obstetricians and Gynaecologists (RCOG). The Journal publishes original, peer-reviewed work in all areas of obstetrics and gynaecology, including contraception, urogynaecology, fertility, oncology and clinical practice. Its aim is to publish the highest quality medical research in women''s health, worldwide.